Eli Lilly is now offering four doses of Zepbound in self-administration vials. The lower-cost self-pay option targets people on Medicare and those who can no longer access compounded tirzepatide.

India's largest drugmaker by revenue Sun Pharmaceutical is aiming to launch its experimental anti-obesity and type 2 diabetes ...

Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.

In Wednesday's "Need to Know" column, Barbara Kollmeyer shared words of wisdom from Larry Swedroe, who has written many books about investing during a long career managing money. He quoted Buffett and ...

Rare Disease Day, an annual gathering hosted by the FDA and National Institutes of Health, was postponed. Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a ...

Eli Lilly announced plans for four new pharmaceutical manufacturing sites to produce domestic medicine production in the ...

Eli Lilly launched an ad campaign on Friday, cautioning patients against the risks of unapproved weight-loss drugs in its ...

That's a potential steal. The average stock in the Health Care Select Sector SPDR Fund trades at a multiple of just under 18 ...

Eli Lilly (LLY) joins hands with Magnet Biomedicine in a deal worth up to $1.25B to develop cancer drugs using Magnet's ...

In a report released today, Geoff Meacham from Citi maintained a Hold rating on Pfizer (PFE – Research Report). The company’s shares closed ...

Eli Lilly is making a massive $50 billion investment in U.S. manufacturing. This move more than doubles their previous $23 ...

Researchers conduct a retrospective, population-based cohort study of adult patients with metastatic breast cancer who underwent genomic profiling at academic institutions.